Keywords: Teva, Fourth-quarter and full-year financial results, Cephalon
Teva Pharma strong sales growth helped by acquisitions
Article | 16 February 2012
Israel-headquartered Teva Pharmaceutical Industries (Nasdaq: TEVA) reported fourth-quarter 2011 results with 28% growth in net revenues to $5.7 billion, driven by generic products ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
